Is er een indicatie voor levenslange antistollingstherapie bij verlaagde (familiaire) antitrombine III-activiteit?
Author:
Middeldorp S.,Briët E.
Publisher
Bohn Stafleu van Loghum
Reference11 articles.
1. Heijboer H, Brandjes DP, Buller HR, Sturk A, Cate JW ten. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Eng J Med 1990; 323: 1512-16.
2. Lane DA, Ireland H, Olds RJ, Thein SL, Perry DJ, Aiach M. Antithrombin III: a database of mutations. Thromb Haemost 1991; 66: 657-61.
3. Tait RC, Walker ID, Perry DJ, et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994; 87: 106-12.
4. Friederich PW, Sanson BJ, Simioni P, et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Int Med 1996; 125: 955-60.
5. Simioni P, Sanson BJ, Prandoni P, Tormene D, Friederich PW, Girolami B, et al. The incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999; 81: 198-202.